Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-338-6 | CAS number: 94-49-5
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- expert QSAR report
- Type of information:
- (Q)SAR
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- results derived from a (Q)SAR model, with limited documentation / justification, but validity of model and reliability of prediction considered adequate based on a generally acknowledged source
Data source
Reference
- Reference Type:
- other company data
- Title:
- Unnamed
- Year:
- 2 017
Materials and methods
Results and discussion
Applicant's summary and conclusion
- Executive summary:
Incentive
Evaluation of the toxicokinetic properties (i.e. absorption, metabolism, distribution and elimination) of the substance is a requirement. The information can contribute in the understanding of the toxicological profile and assist in testing
strategy and study design.
Objective
The purpose of this study was to assess the toxicokinetic properties of ethylene dibenzoate (EGDB, CAS 94-49-5).
Methods
The toxicokinetic properties of EGDB are evaluated using free and commercially available computerized models as well as available study information on the substance itself.
Conclusions
EGDB is a mono-constituent of at least 99.4% purity and has a molecular weight of 270.28 g/mole. It is a solid at room temperature. Based on information from property profiling as well on information on studies on EGDB, the following statements can be made:
- Oral absorption: the bioavailability of EGDB, following dissociation of the salt in the Gastro- Intestinal tract, is considered to be high via oral route. A provisional absorption rate of 100% is set for the oral route.
- Dermal absorption: Dermal absorption of EGDB is expected to be high. A provisional absorption rate of 100% is set for the dermal route.
- Respiratory absorption: Likelihood of exposure via inhalation is low considering the very low vapor pressure. Exposures are only possibly to aerosols that will deposit mainly in upper airways, and will be subsequently swallowed after mucociliary transportation to pharynx. No principal difference is therefore expected in absorption between exposures via inhalation route and oral route as high in respiratory tract. Absorption via inhalation therefore also set to 100%.
- It is predicted that EGDB is rapidly absorbed, distributed over the whole body and excreted again
- EGDB has no bioaccumulation potential (LogPow 3.75 (just above 3) and readily biodegradable).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
